Synthesis and SAR of potent EGFR/erbB2 dual inhibitors

Bioorganic & Medicinal Chemistry Letters
2004.0

Abstract

A series of 6-alkoxy-4-anilinoquinazoline compounds was prepared and evaluated for in vitro inhibition of the erbB2 and EGFR kinase activity. The IC(50) values of the best compounds were below 0.10 uM. Further, several of these compounds inhibit the growth of erbB2 and EGFR over-expressing tumor cell lines at concentrations below 1 uM.

Knowledge Graph

Similar Paper

Synthesis and SAR of potent EGFR/erbB2 dual inhibitors
Bioorganic & Medicinal Chemistry Letters 2004.0
Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors
Bioorganic & Medicinal Chemistry Letters 2007.0
Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors
European Journal of Medicinal Chemistry 2013.0
Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors
Bioorganic & Medicinal Chemistry Letters 2016.0
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: Erlotinib analogs
Bioorganic & Medicinal Chemistry Letters 2014.0
Synthesis and in vitro biological evaluation of novel quinazoline derivatives
Bioorganic & Medicinal Chemistry Letters 2017.0
Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: Dual inhibitors of EGFR and Src protein tyrosine kinases
European Journal of Medicinal Chemistry 2012.0
Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors
European Journal of Medicinal Chemistry 2016.0
Enhancement of EGFR tyrosine kinase inhibition by C–C multiple bonds-containing anilinoquinazolines
Bioorganic & Medicinal Chemistry 2010.0
Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα
European Journal of Medicinal Chemistry 2018.0